DongKoo Bio&Pharma Co. Ltd (006620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DongKoo Bio&Pharma Co. Ltd (006620) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.20 Billion ≈ $810.96K USD) by net assets (₩110.66 Billion ≈ $74.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is DongKoo Bio&Pharma Co. Ltd's balance sheet to measure how much of total assets are equity-financed.
DongKoo Bio&Pharma Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how DongKoo Bio&Pharma Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DongKoo Bio&Pharma Co. Ltd (006620) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
DongKoo Bio&Pharma Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DongKoo Bio&Pharma Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KR1 PLC LS -0019
F:K4H
|
N/A |
|
Medipharm Labs Corp
TO:LABS
|
-0.022x |
|
Fantasia Holdings Group Co. Limited
F:FT7
|
0.018x |
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
-0.008x |
|
Euroholdings Ltd.
NASDAQ:EHLD
|
0.148x |
|
Advance Metals Ltd
AU:AVM
|
-0.047x |
|
Fiplasto SA
BA:FIPL
|
-0.097x |
|
Sephaku Holdings Ltd
JSE:SEP
|
0.054x |
Annual Cash Flow Conversion Efficiency for DongKoo Bio&Pharma Co. Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of DongKoo Bio&Pharma Co. Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see DongKoo Bio&Pharma Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩105.33 Billion ≈ $71.38 Million |
₩17.34 Billion ≈ $11.75 Million |
0.165x | +407.23% |
| 2023-12-31 | ₩110.44 Billion ≈ $74.85 Million |
₩3.59 Billion ≈ $2.43 Million |
0.032x | -80.29% |
| 2022-12-31 | ₩102.11 Billion ≈ $69.20 Million |
₩16.82 Billion ≈ $11.40 Million |
0.165x | -7.88% |
| 2021-12-31 | ₩100.12 Billion ≈ $67.85 Million |
₩17.90 Billion ≈ $12.13 Million |
0.179x | +126.00% |
| 2020-12-31 | ₩94.65 Billion ≈ $64.14 Million |
₩7.49 Billion ≈ $5.08 Million |
0.079x | -33.16% |
| 2019-12-31 | ₩85.65 Billion ≈ $58.05 Million |
₩10.14 Billion ≈ $6.87 Million |
0.118x | +1178.70% |
| 2018-12-31 | ₩72.10 Billion ≈ $48.86 Million |
₩-791.20 Million ≈ $-536.19K |
-0.011x | -104.36% |
| 2017-12-31 | ₩37.74 Billion ≈ $25.58 Million |
₩9.51 Billion ≈ $6.44 Million |
0.252x | -55.89% |
| 2016-12-31 | ₩22.05 Billion ≈ $14.94 Million |
₩12.59 Billion ≈ $8.53 Million |
0.571x | -79.00% |
| 2015-12-31 | ₩2.55 Billion ≈ $1.73 Million |
₩6.93 Billion ≈ $4.70 Million |
2.719x | -- |
About DongKoo Bio&Pharma Co. Ltd
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more